epidemiologyЭпидемиология и ВакцинопрофилактикаEpidemiology and Vaccinal Prevention2073-30462619-0494«Numicom» LLC10.31631/2073-3046-2015-14-4-29-35epidemiology-378Research ArticleЭПИДЕМИОЛОГИЯEPIDEMIOLOGYПарвовирусная инфекция – современная проблема в эпидемиологии и клинической медицинеParvovirus Infection – Contemporary Issues in Epidemiology and Clinical MedicineНикишовО. Н.NikishovO. N.Muxaujio@yandex.ruКузинА. А.KuzinA. A.АнтиповаА. Ю.AntipovaA. Yu.anti130403@mail.ruЛаврентьеваИ. Н.Lavrent’evaI. N.pasteur.lawr@mail.ruФГБВОУ ВПО «Военно-медицинская академия им. С.М. Кирова» Минобороны РоссииРоссияFederal State Military Educational Institution of Additional Professional Education «Military Medical Academy named S.M. Kirov» Ministry of Defense of the Russian FederationRussian FederationФБУН «НИИ эпидемиологии и микробиологии имени Пастера»РоссияFederal Budgetary Institution of Science «Pasteur Research Institute of Epidemiology & Microbiology»Russian Federation2015200820151442935Copyright © Никишов О.Н., Кузин А.А., Антипова А.Ю., Лаврентьева И.Н., 20152015Никишов О.Н., Кузин А.А., Антипова А.Ю., Лаврентьева И.Н.Nikishov O.N., Kuzin A.A., Antipova A.Y., Lavrent’eva I.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epidemvac.ru/jour/article/view/378

Для здравоохранения Российской Федерации парвовирусная инфекция (PV B19) представляет собой важную, но малоизученную проблему. Ее клинические проявления разнообразны, что требует дифференциальной диагностики как с другими вирусными инфекциями, так и с неинфекционными заболеваниями. Эпидемиологическая значимость PV B19 определяется широким распространением эпидемических вспышек – преимущественно в организованных коллективах. Медико-социальная значимость связана также с тератогенным действием вируса, а также возможностью его передачи при гематрансфузиях – отсюда к основным группам риска относят беременных женщин и пациентов гематологического профиля. При отсутствии регистрации и учета заболеваемости людей невозможно установить масштаб распространения парвовирусной инфекции. Решающее значение в этом вопросе имеют лабораторные исследования, позволяющие выявлять маркеры PV B19. 

Parvovirus infection (PVI) is an important but little-known problem in the Russian Federation. Its clinical manifestations are characterized by different clinical entities that require differential diagnosis, as with other viral infections, as well as non-communicable diseases and epidemiological significance of PVI determined the prevalence of the development of epidemic outbreaks, mainly in organized groups. Medical and social - with teratogenic virus, as well as the possibility of its transmission at gematransfuziyah. The main risk groups - pregnant women, patients hematological profile. In the absence of recording and reporting the incidence of people is impossible to establish the scale of the spread of parvovirus infection. Crucial in this respect are laboratory studies that reveal the prevalence of its laboratory markers. 

парвовирусная инфекцияпарвовирус человека В19PV B19донорыбеременностьсыпьрarvovirus B19 infectiondonorspregnancyrashReferencesАнтипова А.Ю., Лаврентьева И.Н., Бичурина М.А., Лялина Л.В., Кутуева Ф.Р. Распространение парвовирусной инфекции в Cеверо-Pападном федеральном округе России. Ж. инфектологии. 2011; 3 (4): 44 – 48.Antipovа A. Y., Lavrentievа I.N., Bichurina M.A., Lyalina L.V., Kutueva F.R. et al. The spread of parvovirus infection in the Northwestern federal district of Russia. J. Infectology. 2011; 3 (4): 44 – 48 (in Russian).Антипова, А.Ю. Значение лабораторной диагностики краснушной и парвовирусной инфекций в период элиминации краснухи. Дис. … канд. биол. наук. Санкт-Петербург; 2013: 23.Antipovа A.Y. The value of laboratory diagnosis of rubella and parvovirus infection in the elimination of rubella: Doctorate of biol. sci. diss. Science. Saint Petersburg: 2013: 23 (in Russian).Cossart Y.E., Field A.M., Cant B., Widdows D. Parvovirus-like particles in human sera. Lanset. 1975; 1: 137 – 142.Cossart Y.E., Field A.M., Cant B., Widdows D. Parvovirus-like particles in human sera. Lanset. 1975; 1: 137 – 142.International Committee on Taxonomy of Viruses. Доступно на: http://ictvonline.org/virusTaxonomy.aspInternational Committee on Taxonomy of Viruses. Available at: http://ictvonline.org/virusTaxonomy.aspMori J., Beattie P., Melton D.W. et al. Structure and mapping of the DNA of human parvovirus B19. J. Gen. Virol. 1987; 68: 2797 – 2806.Mori J., Beattie P., Melton D.W., Cohen B.J,Clewley J.P. Structure and mapping of the DNA of human parvovirus B19. J. Gen. Virol. 1987; 68: 2797 – 2806.Young N.S., Brown K.E. Mechanisms of disease: Parvovirus. N. Engl. J. Med. 2004; 350 (6): 586 – 597.Young N.S., Brown K.E. Mechanisms of disease: Parvovirus. N. Engl. J. Med. 2004; 350 (6): 586 – 597.Алимбарова Л.М. Парвовирусы (Parvoviridae). В кн. Руководство по медицинской вирусологии. Львов Д.К., ред. Москва: 2008: 276 – 284.Alimbarova L.M. Parvovirus (Parvoviridae). Proc. Manual of Medical Virology, ed. Lvov DK, Moscow 2008: 276 – 284 (in Russian).Amand St., Astell J., Astell C.R. Indentification and сharacterization of a family of 11-kDa proteins encoded by hyman parvovirus B19. Virology. 1993; 192: 121 – 131.Amand St., Astell J., Astell C.R. Indentification and sharacterization of a family of 11-kDa proteins encoded by hyman parvovirus B19. Virology. 1993; 192: 121 – 131.Лаврентьева И.Н.. Антипова А.Ю. Парвовирус В19 человека: характеристика, возбудителя и диагностика обусловленной им инфекции. Инфекция и иммунитет. 2012; 4: 314 – 316.Lavrentiev I.N., Antipovа A.Yu. Human parvovirus B19: characterization and diagnosis of pathogen infections caused by them. Infection and Immunity. 2012; 4: 314 – 316 (in Russian).Baylis S.A. Standardization of nucleic acid amplification technique (NAT)-based assays for different genotypes of parvovirus B19: a meeting summary. Vox Sanguinis. 2008; 94: 74 – 80.Baylis S.A. Standardization of nucleic acid amplification technique (NAT) -based assays for different genotypes of parvovirus B19: a meeting summary. Vox Sanguinis. 2008; 94: 74 – 80.Corcoran A., Doyle S., Advances in the biology, diagnosis and host-pathogen interactionsof parvovirus B19, J. Med. Microbiol. 2004; 53: 459 – 475.Corcoran A., Doyle S. Advances in the biology, diagnosis and host-pathogen interactionsof parvovirus B19, J. Med. Microbiol. 2004; 53: 459 – 475.Andersоn L.J. et al. Risk of infection following exposures to human parvovirus B19. Behring Inst. Mitt. 1990; 85: 60-63.Anderson L.J., Gillespie S.M., Torok T.J., Hurwitz E.S., Tsou C. J., Gary G.W.. Risk of infection following exposures to human parvovirus B19. Behring Inst. Mitt. 1990; 85: 60 – 63.Blumel J., Eis-Hubinger A.M., Stuhler A., Bonsch et al. Characterization of Parvovirus B19 genotypes 2 in KU812Ep6 cells. J.Virol. 2005; 79 (22): 14197 – 14206.Blumel J., Eis-Hubinger A.M., Stuhler A., Bonsch C., Gessner M., Lower J. Characterization of Parvovirus B19 genotypes 2 in KU812Ep6 cells. J.Virol. 2005; 79 (22): 14197 – 14206.Lou S., Xu B., Xuang Q., Zhi N., Cheng F. et al. Molecular сharacterization of the newly identified human parvovirus 4 in the family Parvoviridae. Virology. 2012, 422: 59 – 69.Lou S., Xu B., Xuang Q., Zhi N., Cheng F., Wong S., Brown K. Molecular sharacterization of the newly identified human parvovirus 4 in the family Parvoviridae. Virology. 2012, 422: 59 – 69.Ливада А.И. Парвовирусная В19-инфекция. Педиатр онлайн. 2012.Livada A.I. Parvovirus B19 infection. Pediatrician online. 2012 (in Russian).Allander N. et al. Cloing of a human parvovirus by molecular screening of respiratory tract samples. Proc. Natl Acad. Sci. U.S.A. 2005; 102: 12891 – 12896.Allander N. Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. Cloing of a human parvovirus by molecular screening of respiratory tract samples. Proc. Natl Acad. Sci. U.S.A. 2005; 102: 12891 – 12896.Смеликов Я.А., Парвовирусная (В19) инфекция у детей на современном этапе (обзор). Вестник КГМА им. И.К. Ахунбаева. 2011; 4: 20 – 24.Smelik J.A., Parvovirus (B19) infection in children at the present stage (review). Bulletin of KSMA them. I.K. Ahunbaeva. 2011; (4): 20 – 24 (in Russian).Международная классификация болезней (МКБ 10). Доступно на: http://www.zakonprost.ru/International Classification of Diseases (ICD-10). Available at: http://www.cdc.gov/ (in Russian).Тихонова Н.Т. Оценка распространения парвовирусной инфекции в Москве. Информационное письмо Комитета здравоохранения г. Москвы. Москва; 2004; (11): 12.Tikhonovа N.T. Evaluation of the spread of parvovirus infection in Moscow. Information Letter of the Health Committee of Moscow. Moscow; 2004; (11): 12 (in Russian).Лушнова И.В. Парвовирусная В19 инфекция. Педиатр. 2010; 1: 115 – 118.Lushnova I.V. Parvovirus B19 infection. Pediatrician. 2010; 1: 115 – 118 (in Russian).Broliden K., Tolfvenstam T., Norbeck O. Clinical aspects of parvovirus B19 infection. J. Intern. Med. 2006; 260: 285 – 304.Broliden K., Tolfvenstam T., Norbeck O. Clinical aspects of parvovirus B19 infection. J. Intern. Med. 2006; 260: 285 – 304.Gustafsson I. Evolution of Parvovirus B19 infection in children with malignant or hematological disorders. Clin. Infect. Dis. 2010; 50 (10): 1426 – 1427.Gustafsson I., Evolution of Parvovirus B19 infection in children with malignant or hematological disorders. Clin. Infect. Dis. 2010; 50 (10): 1426 – 1427.Лаврентьева И.Н., Антипова А.Ю., Семенов А.Н., Бичурина М.А. Генотипирование изолятов паврвовируса В19, циркулирующих в Северо-Западном округе Российской Федерации. Журн. микробиол. 2013; 6: 36 – 43.Lavrentieva I.N., Antipova A.Yu., Semenov, A.N., Bichurina M.A. Genotyping of isolates pavrvovirusa B19, circulating in the Northwest region of the Russian Federation. Zh. microbiology. 2013; 6: 36 – 43 (in Russian).Wong A., Tan K.H., Tee C.S., Yeo G.S.H. Seroprevalence of Cytomegalovirus, Toxoplasma and parvovirus in pregnancy. Signapore Med J. 2000; 1 (4): 151 – 155.Wong A., Tan K.H., Tee C.S., Yeo G.S.H. Seroprevalence of Cytomegalovirus, Toxoplasma and parvovirus in pregnancy. Signapore Med J. 2000; 1 (4): 151 – 155 (in Russian).Васильев В.В., Мурина Е.А., Сидоренко С.В., Мукомолова А.Л. и др. Парвовирусная (В19V) инфекция у беременных и детей раннего возраста. Журнал инфектологии. 2011; 3 (4): 26 – 33.Vasiliev V.V., Murin E.A., Sidorenko S.V, Mukomolova A.L. et al. Parvovirus (V19V) infection in pregnant women and young children. Journal infektologii. 2011; 3 (4): 26 – 33.Centres for Disease Control. Current trends risks associated with human Parvovirus B19 infection. MMWR. 1989; 38 (6): 81 – 88, 93 – 97 Доступно на: http//www.cdc.gov/mmwr/preview/mmwrhtm/ 00001348.htm.Centres for Disease Control. Current trends risks associated with human Parvovirus B19 infection. MMWR Morb Mortal WKLY Rep. 1989; 38 (6): 81 – 88, 93 – 97. Available at: httр://www.cdc.gov/mmwr/preview/mmwrhtm/00001348.htm.Jones M.S., New DNA viruses identified in patiens with acute viral infection syndrome, J. Virol. 2005; 79: 8230 – 8236.Jones M.S. New DNA viruses identified in patiens with acute viral infection syndrome, J. Virol. 2005; 79: 8230 – 8236.Savaresi I., Atypical manifestations of congenital parvovirus B19 infection. Eur. J. Pediatr. 2008; 167 (12): 1463 – 1466.Savaresi I. Atypical manifestations of congenital parvovirus B19 infection. Eur. J. Pediatr. 2008; 167 (12): 1463 – 1466.Bernuau J., Durand F., Valla D. Parvovirus B19 infection and ful-minant hepatitis. Lancet. 1999; 353 (9154): 754 – 755.Bernuau J., Durand F., Valla D. Parvovirus B19 infection and ful-minant hepatitis. Lancet. 1999; 353 (9154): 754 – 755.Abe K., Kiuchi T., Tanaka K. Edamoto Y, Aiba N, Sata T. Characterization of erythrovirus B19 genomes isolated in liver tissues from patients with fulminant hepatitis and biliary atresia who underwent liver transplantation. Int. J. Med. Sci. 2007; 4(2): 105 – 109.Abe K., Kiuchi T., Tanaka K. Edamoto Y, Aiba N, Sata T.. Characterization of erythrovirus B19 genomes isolated in liver tissues from patients with fulminant hepatitis and biliary atresia who underwent liver transplantation. Int. J. Med. Sci. 2007; 4 (2): 105 – 109.Botto S., Bergallo M., Sidoti F., Terlizzi M.E., Astegiano S., Ponti R. et al. Detection of PARV4, genotypes 1 and 2, in healthy and pathological clinical specimens. New Microbiol. 2009; 32: 189 – 192.Botto S., Bergallo M., Sidoti F., Terlizzi ME, Astegiano S., Ponti R. et al. Detection of PARV4, genotypes 1 and 2, in healthy and pathological clinical specimens. New Microbiol. 2009; 32: 189 – 192.Ekman A., Hokynar K., Kakkola L., Kantola K., Hedman L.., Soderlund-Venermo M. Biologikal and immunological relations among Human Parvovirus B19 genotypes 1 to 3. О. Virol. 2007; 81 (13): 6927 – 6935.Ekman A., Hokynar K., Kakkola L., Kantola K., Hedman L. et al. Soderlund-Venermo M. Biologikal and immunological relations among Human Parvovirus B19 genotypes 1 to 3. Virol. 2007; 81 (13): 6927 – 6935.Климович Н.В., Матвеев В.А., Романова О.Н., Черновецкий М.А. Эпидемиологическая характеристика парвовирусной инфекции у детей с гематологическими заболеваниями. Охрана материнства и детства. 2011; 1: 42 – 46.Klimovich N.V., Matveev V.A., Romanov O.N., Chernivtsi M.A. Epidemiological characteristics of parvovirus infection in children with hematological diseases. Maternal and child health. 2011; 1: 42 – 46 (in Russian).Brown K.E., Hibbs J.R., Gallinella G., Anderson S.M. Resistance to Parvovirus B19 infection due to lack of virusreceptor (erythrocyte P antigen). N. Engl. J. Med. 1994; 330 (17): 1192 – 1196.Brown K.E., Hibbs J.R., Gallinella G., Anderson S.M., Lehman E.D., McCarthy P. Resistance to Parvovirus B19 infection due to lack of virusreceptor (erythrocyte P antigen). N. Engl. J. Med. 1994; 330 (17): 1192 – 1196.Weigel-Kelley K.A., Yoder M.C., Srivastava A.Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transductionof human hematopoietic cells. J. Virol. 2001; 75 (9): 4110 – 4116.Weigel-Kelley K.A., Yoder M.C., Srivastava A. Recombinant human parvovirus B19 vectors: erythrocyte P antigen is necessary but not sufficient for successful transductionof human hematopoietic cells. J. Virol. 2001; 75 (9): 4110 – 4116.Jordan J.A., DELoia J.A. Globoside expression within the human placenta. Placenta. 1999; 20: 103 – 108.Jordan J.A., DELoia J.A. Globoside expression within the human placenta. Placenta. 1999; 20: 103 – 108.Riipinen A., Vaisanen E., Nuutila M., Sallmen V., Karikoski R., Lindbohm M.-L.. Parvovirus B19 infection in fetal deaths. CID. 2008; (47): 1519 – 1525.Riipinen A., Vaisanen E., Nuutila M., Sallmen V. et al. Parvovirus B19 infection in fetal deaths. CID. 2008; (47): 1519 – 1525.Riipinen, A. Parvovirus B19 infection in fetal deaths. CID. 2008; (47): 1519 – 1525.Riipinen A. Parvovirus B19 infection in fetal deaths. CID. 2008; (47): 1519 – 1525.Schwarz T.F., Nerlich А, Hillemanns Р. Detection of parvovirus B19 in fetal autopsies Arch. Gynecol. Obstet.1999; 253 (4): 207 – 213.Schwarz T.F., Nerlich A., Hillemanns R. Detection of parvovirus B19 in fetal autopsies Arch. Gynecol. Obstet.1999; 253 (4): 207 – 213.Wong A. Seroprevalence of Cytomegalovirus, Toxoplasma and parvovirus in pregnancy Singapore Med J. 2000; 1 (4): 151 – 155.Wong A. Seroprevalence of Cytomegalovirus, Toxoplasma and parvovirus in pregnancy. Singapore Med. J. 2000; 1 (4): 151 – 155.De Jong E.P. Parvovirus B19 infection in pregnancy. J. Clin. Virol. 2006; 36: 1 – 7.De Jong E.P. Parvovirus B19 infection in pregnancy. J. Clin. Virol. 2006; 36: 1 – 7.Porter H.J., Quantrill A.M., Fleming K.A. B19 parvovirus infection of myocardial cells. Lancet. 1988; 1: 535 – 536.Porter H.J., Quantrill A.M., Fleming K.A. B19 parvovirus infection of myocardial cells. Lancet. 1988; 1: 535 – 536.Young N.S., Brown K.E. Mechanisms of disease: Parvovirus B19. Engl. J. Med. 2004; 350 (6): 586–597.Young, N.S., Brown K.E. Mechanisms of disease: Parvovirus B19 Engl. J. Med. 2004; 350 (6): 586 – 597.Crane J., Mundle W., Boucoiran I., Matemal Fetal Medicine Committee, Gagnon R., Bujold E., Basso M. Parvovirus B19 infection in pregnancy. J. Obstet. Gyneacol. Can. 2014; 36 (12): 1107 – 1116. Доступно на: http://www. ncbi.nlm.nih.gov/pubmed/25668048; http://sogc.org/wp-content/ uploads/2014/12/gui3161012E.pdf.Crane J., Mundle W., Boucoiran I. Matemal Fetal Medicine Committee, Gagnon R., Bujold E., Basso M. Parvovirus B19 infection in pregnancy. J. Obstet. Gyneacol. Can. 2014; 36 (12): 1107 – 1116. Available at: http://www. ncbi.nlm.nih.gov/pubmed/25668048; http://sogc.org/wp-content/ uploads/2014/12/ gui3161012E.pdf.Anderson L.J., Tsou C., Parker R.A., Chorba T.L., Wulff H., Tattersal P. . Detection of antibodies and antigens of human parvovirus B19 by enzume-linked immunosorbent assay. J. Clin. Microbiol. 1986; 24: 522 – 526.Anderson L.J., Tsou C., Parker R.A,. Chorba T.L., Wulff H., Tattersal P. . Detection of antibodies and antigens of human parvovirus B19 by enzume-linked immunosorbent assay. J. Clin. Microbiol. 1986; 24: 522 – 526.Heegaard E.D., Brown K.E. Human parvovirus B19. Clinical microbiology reviews. 2002; 15(3): 485 – 505.Heegaard E.D., Brown K.E. Human parvovirus B19. Clinical microbiology reviews. 2002; 15 (3): 485 – 505.Антипова, А.Ю. Значение лабораторной диагностики краснушной и парвовирусной инфекций в период элиминации краснухи: автореф. дис. … канд. биол. наук Санкт-Петербург; 2013: 23.Antipovа A.Y. The value of laboratory diagnosis of rubella and parvovirus infection in the elimination of rubella:.Doctorate of biol. sci. diss. St. Petersburg; 2013. 23 (in Russian).Диагностика инфекций, вызванных парвовирусом B. Режим доступа: http://www.cirlab.ru/library/73/4554 (03.03.2015.).Diagnosis of infections caused by parvovirus B.Available at http://www.cirlab.ru/library/73/4554.Giorgio E., De Oronzo M.A., Iozza I., Di Natale A., Cianci S., Garofalo G. et al. Parvovirus B19 during pregnancy. J. оf Prenatal Medicicne. 2010; 4 (4): 63-66.Giorgio E., De Oronzo M.A., Iozza I., Di Natale A., Cianci S., Garofalo G. et al. Parvovirus B19 during pregnancy. J. оf Prenatal Medicicne. 2010; 4 (4): 63 – 66.Fairley C.K., Smoleniec J.S., Caul O.E., Miller E. Observational study of effect of intrauterine transfusion on outcome of fetal hydrops after parvovirus B19 infection. Lancet 1995; 346: 1335.Fairley C.K., Smoleniec J.S., Caul O.E., Miller E. Observational study of effect of intrauterine transfusion on outcome of fetal hydrops after parvovirus B19 infection. Lancet 1995; 346: 1335.Mossong, J., Hens N., Friederichs V., Davidkin I., Broman M., Litwincka B. et al. Parvovirus B19 infection in the European countries: seroepidemiology, force of infection, and maternal risk of infection. Epidemiol. Infect. 2008; 136 (8): 1059 – 1068.Mossong, J. et al. Parvovirus B19 infection in the European countries: seroepidemiology, force of infection, and maternal risk of infection. Epidemiol. Infect. 2008; 136 (8): 1059 – 1068.Gillespie S.M., Cartter M.L., Asch S., Rokos J.B. Occupational risk of human parvovirus B19 infection forschool and day-care personnel during an outbreak of erythema infectiosum. J. Am. Med. Assoc. 1990; 263 (15): 2061 – 2065.Gillespie S.M., Cartter M.L., Asch S., Rokos J.B., Tsou C. J., Gary G. Occupational risk of human parvovirus B19 infection forschool and day-care personnel during an outbreak of erythema infectiosum. J. Am. Med. Assoc. 1990; 263 (15): 2061 – 2065.Enders, M. Weidner А., Enders G. Current epidemiological aspects of human parvovirus B19 infection during pregnancy and childhood in the western part of Germany. Epidemiol. Infect. 2007; 135: 563 – 569.Enders M. Current epidemiological aspects of human parvovirus B19 infection during pregnancy and childhood in the western part of Germany M. Enders, A. Weidner, G. Enders. Epidemiol. Infect. 2007; 135: 563 – 569.Медведева В.В., Скородумова Н.П., Кучеренко Н.П., Гончарова Л.А., Коваленко Т.И., Легкая В.А. и др. Клинико-эпидемиологические особенности регистрации парвовирусной инфекции в Донецком регионе. Медико-социальные проблемы семьи. 2013; 2 (18): 98 – 101.Medvedeva V.V.,Skorodumova N.P., Kucherenko N.P., Goncharova L.A., Kovalenko T.I., Legkaya V.A. et al. Clinical and epidemiological features of parvovirus infection detection in Donetsk region. Medical-social problems of the family. 2013; 2 (18): 98 – 101 (in Russian).Филатова Е.В., Новикова Н.А., Зубкова Н.В., Голицына Л.Н., Кузнецов К.В. Определение маркеров парвовируса В19 в образцах крови доноров. Журнал микробиологии. 2010; 5: 67 – 70.Filatova E.V., Novikova N.A., Zubkov N.V., Golitsyn L.N., Kuznetsov K.V. Determination of markers in samples of the parvovirus B19 blood donor. Journal of Epidemiology and Microbiology, Immunology. 2010; 5: 67 – 70 (in Russian).Элижбаева М.А. Парвовирус В19 у доноров крови и больных гематологического стационара. Дис. … канд. биол. наук. Москва; 2011.Elizhbaeva M.A. Parvovirus B19 in blood donors and patients with hematological hospital. Doctorate of med. sci. diss. Moscow;2011 (in Russian).Candotti D., Etiz N., Parsyan A., Allain J.-P.et . Indentification and сharacterization of persistent human erythrovirus infection in blood donor samples. J. Virol. 2004; 78: 12169-12178.Candotti D., Etiz N., Parsyan A. et al. Indentification and sharacterization of persistent human erythrovirus infection in blood donor samples. J. Virol. 2004; 78: 12169 – 12178.Candotti D., Etiz N., Parsyan A. Allain J.-P. Indentification and сharacterization of persistent human erythrovirus infection in blood donor samples. J. Virol. 2004; 78: 12169 – 12178.Candotti D., Etiz N., Parsyan A. et al. Indentification and sharacterization of persistent human erythrovirus infection in blood donor samples. J. Virol. 2004; 78: 12169 – 12178.Парвовирусная инфекция. Доступно на: http: // www.pitermed.com / simptomy-bolezni /?Cat = 6&word = 54191 (03.03.2015.).Parvovirus infection. Available at: http: // www.pitermed.com / simptomy-bolezni /? Cat = 6 & word = 54191 (03.03.2015.).

The authors declare that there are no conflicts of interest present.